150 related articles for article (PubMed ID: 28533806)
1. Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer.
Maenhout M; van Vulpen M; Moerland M; Peters M; Meijer R; van den Bosch M; Nguyen P; Frank S; van der Voort van Zyp J
J Contemp Brachytherapy; 2017 Apr; 9(2):161-166. PubMed ID: 28533806
[TBL] [Abstract][Full Text] [Related]
2. Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer.
Maenhout M; Peters M; van Vulpen M; Moerland MA; Meijer RP; van den Bosch MAAJ; Nguyen PL; Frank SJ; van der Voort van Zyp JRN
Technol Cancer Res Treat; 2017 Dec; 16(6):1194-1201. PubMed ID: 29333958
[TBL] [Abstract][Full Text] [Related]
3. Focal salvage treatment for radiorecurrent prostate cancer: A magnetic resonance-guided stereotactic body radiotherapy versus high-dose-rate brachytherapy planning study.
Willigenburg T; Beld E; Hes J; Lagendijk JJW; de Boer HCJ; Moerland MA; van der Voort van Zyp JRN
Phys Imaging Radiat Oncol; 2020 Jul; 15():60-65. PubMed ID: 33458327
[TBL] [Abstract][Full Text] [Related]
4. F-SHARP: a Phase I/II trial of focal salvage high-dose-rate brachytherapy for Radiorecurrent prostate cancer.
Solanki AA; Yoo RK; Adams W; Davicioni E; Mysz ML; Shea S; Gupta GN; Showalter T; Garant A; Hentz C; Farooq A; Baldea K; Small W; Harkenrider MM
BJU Int; 2024 Feb; 133(2):188-196. PubMed ID: 37562825
[TBL] [Abstract][Full Text] [Related]
5. MRI-Guided Ultrafocal Salvage High-Dose-Rate Brachytherapy for Localized Radiorecurrent Prostate Cancer: Updated Results of 50 Patients.
van Son MJ; Peters M; Moerland MA; Lagendijk JJW; Eppinga WSC; Shah TT; Ahmed HU; van der Voort van Zyp JRN
Int J Radiat Oncol Biol Phys; 2020 May; 107(1):126-135. PubMed ID: 32006609
[TBL] [Abstract][Full Text] [Related]
6. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control.
Mayrata E; Espinosa JM; Büchser D; Casquero F; Suárez F; González A; Minguez P; Pérez JF; Miguel IS; Cacicedo J; Gómez-Iturriaga A
J Contemp Brachytherapy; 2021 Feb; 13(1):12-17. PubMed ID: 34025731
[TBL] [Abstract][Full Text] [Related]
7. MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life.
Maenhout M; Peters M; Moerland MA; Meijer RP; van den Bosch MAAJ; Frank SJ; Nguyen PL; van Vulpen M; van der Voort van Zyp JRN
Radiother Oncol; 2018 Dec; 129(3):554-560. PubMed ID: 30131183
[TBL] [Abstract][Full Text] [Related]
8. Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer.
Zamboglou C; Rischke HC; Meyer PT; Knobe S; Volgeova-Neher N; Kollefrath M; Jilg CA; Grosu AL; Baltas D; Kroenig M
J Contemp Brachytherapy; 2016 Jun; 8(3):241-8. PubMed ID: 27504134
[TBL] [Abstract][Full Text] [Related]
9. Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy.
Buchser D; Gomez-Iturriaga A; Melcon JI; Casquero F; Llarena R; Cacicedo J; Bilbao P
J Contemp Brachytherapy; 2016 Dec; 8(6):477-483. PubMed ID: 28115952
[TBL] [Abstract][Full Text] [Related]
10. Development and internal validation of multivariable prediction models for biochemical failure after MRI-guided focal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer.
Willigenburg T; van Son MJ; van de Pol SMG; Eppinga WSC; Lagendijk JJW; de Boer HCJ; Moerland MA; van der Voort van Zyp JRN; Peters M
Clin Transl Radiat Oncol; 2021 Sep; 30():7-14. PubMed ID: 34278009
[TBL] [Abstract][Full Text] [Related]
11. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
[TBL] [Abstract][Full Text] [Related]
12. Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial.
Murgic J; Morton G; Loblaw A; D'Alimonte L; Ravi A; Wronski M; Davidson M; Haider M; Commisso K; Zhang L; Chung HT
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):561-567. PubMed ID: 30244878
[TBL] [Abstract][Full Text] [Related]
13. Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients.
van Son M; Peters M; Moerland M; van de Pol S; Eppinga W; Lagendijk J; van der Voort van Zyp J
Clin Transl Radiat Oncol; 2021 Mar; 27():1-7. PubMed ID: 33364450
[TBL] [Abstract][Full Text] [Related]
14. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
15. Recurrence characteristics after focal salvage HDR brachytherapy in prostate cancer.
Rasing MJA; Peters M; van Son M; Moerland MA; Eppinga W; van de Pol SMG; Noteboom J; Lagendijk J; van der Voort van Zyp JRN
Radiother Oncol; 2023 Mar; 180():109495. PubMed ID: 36708924
[TBL] [Abstract][Full Text] [Related]
16. Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome.
Jiang P; van der Horst C; Kimmig B; Zinsser F; Poppe B; Luetzen U; Juenemann KP; Dunst J; Siebert FA
Brachytherapy; 2017; 16(1):186-192. PubMed ID: 28341011
[TBL] [Abstract][Full Text] [Related]
17. Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity.
Rose JN; Crook JM; Pickles T; Keyes M; Morris WJ
Brachytherapy; 2015; 14(3):342-9. PubMed ID: 25727178
[TBL] [Abstract][Full Text] [Related]
18. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
Peters M; van der Voort van Zyp J; Hoekstra C; Westendorp H; van de Pol S; Moerland M; Maenhout M; Kattevilder R; van Vulpen M
Radiother Oncol; 2015 Nov; 117(2):262-9. PubMed ID: 26349590
[TBL] [Abstract][Full Text] [Related]
19. The effect of catheter displacement and anatomical variations on the dose distribution in MRI-guided focal HDR brachytherapy for prostate cancer.
Maenhout M; van der Voort van Zyp JRN; Borot de Battisti M; Peters M; van Vulpen M; van den Bosch M; Moerland MA
Brachytherapy; 2018; 17(1):68-77. PubMed ID: 28579419
[TBL] [Abstract][Full Text] [Related]
20. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]